journal article·2025-07-04

ROS-Responsive T1/T2 Mode-Switchable MRI Contrast Agents for Tumor Diagnosis

Mengke Fan, Taotao Chu, Mingya Tan, Jiayi Zhao, Xianghua Yang, Zhenghuan Zhao, Zhiping Peng

ACS Applied Nano Materials· Volume 8· Issue 26
Publisher page

Abstract

To overcome the limitations of traditional contrast agents in terms of targeting and diagnostic sensitivity, we present superparamagnetic nanoclusters (Ncs) in combination with rationally designed nanocarriers for accurate tumor diagnosis. The Ncs were formed by monodisperse superparamagnetic manganese ferrite linked by thioketal bonds, which behave as T 2 contrast agents in normal tissues in vivo. The thioketal bonds within the Ncs break once they enter the tumor microenvironment response to its high reactive oxygen species (ROS) level, which achieves imaging mode flipping. The T 1 / T 2 switchable contrast greatly improves the MRI contrast of the disease, provides more information about the site of the lesion, and makes the diagnosis more accurate.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Lanthanide and Transition Metal Complexes · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Basic Medical Sciences

Chongqing Medical University

Funding

Creative Research Group of CQ University

References (44)

Show source-provided references
1. 10.1038/s41571-024-00891-110.1038/s41571-024-00891-1 ↗
2. 10.3390/cancers1701007410.3390/cancers17010074 ↗
3. 10.1136/jitc-2022-00470810.1136/jitc-2022-004708 ↗
4. 10.1002/adhm.20230060210.1002/adhm.202300602 ↗
5. 10.1097/RLI.000000000000103010.1097/RLI.0000000000001030 ↗
6. 10.1002/jmri.2958910.1002/jmri.29589 ↗
7. 10.1002/wnan.180010.1002/wnan.1800 ↗
8. 10.1039/D2TB01855A10.1039/D2TB01855A ↗
9. 10.1016/j.actbio.2022.05.02410.1016/j.actbio.2022.05.024 ↗
10. 10.1016/j.jconrel.2021.02.03010.1016/j.jconrel.2021.02.030 ↗
11. 10.1016/j.actbio.2023.04.00310.1016/j.actbio.2023.04.003 ↗
12. 10.1002/EXP.2022000210.1002/EXP.20220002 ↗
13. 10.1039/D0NR08039J10.1039/D0NR08039J ↗
14. 10.1021/acs.analchem.1c0312810.1021/acs.analchem.1c03128 ↗
15. 10.1021/acsnano.4c0172310.1021/acsnano.4c01723 ↗
16. 10.1021/acsami.1c2274710.1021/acsami.1c22747 ↗
17. 10.1021/acsami.0c0728810.1021/acsami.0c07288 ↗
18. 10.1039/D1TB01018B10.1039/D1TB01018B ↗
19. 10.7150/thno.10350310.7150/thno.103503 ↗
20. 10.1021/acsabm.3c0000710.1021/acsabm.3c00007 ↗
21. 10.1021/acsanm.4c0545210.1021/acsanm.4c05452 ↗
22. 10.1002/adhm.20230393910.1002/adhm.202303939 ↗
23. 10.1186/s12951-022-01363-310.1186/s12951-022-01363-3 ↗
24. 10.1007/s41061-020-00302-w10.1007/s41061-020-00302-w ↗
25. 10.3390/pharmaceutics1312214810.3390/pharmaceutics13122148 ↗
26. 10.3390/nano807046610.3390/nano8070466 ↗
27. 10.1039/c3tb00037k10.1039/c3tb00037k ↗
28. 10.1038/s41392-022-01270-x10.1038/s41392-022-01270-x ↗
29. 10.1021/acs.accounts.4c0069110.1021/acs.accounts.4c00691 ↗
30. 10.1021/acs.bioconjchem.3c0047610.1021/acs.bioconjchem.3c00476 ↗
31. 10.1016/j.actbio.2024.06.00210.1016/j.actbio.2024.06.002 ↗
32. 10.1016/j.actbio.2024.02.04810.1016/j.actbio.2024.02.048 ↗
33. 10.1016/j.carbpol.2021.11908710.1016/j.carbpol.2021.119087 ↗
34. 10.1186/s12951-024-02389-510.1186/s12951-024-02389-5 ↗
35. 10.1186/s12951-021-01136-410.1186/s12951-021-01136-4 ↗
36. 10.7150/thno.4957710.7150/thno.49577 ↗
37. 10.1016/j.actbio.2023.10.01910.1016/j.actbio.2023.10.019 ↗
38. 10.1039/D2BM00667G10.1039/D2BM00667G ↗
39. 10.1021/acs.nanolett.4c0266910.1021/acs.nanolett.4c02669 ↗
40. 10.3390/molecules2906135210.3390/molecules29061352 ↗
41. 10.1097/RLI.000000000000103110.1097/RLI.0000000000001031 ↗
42. 10.1039/D3AN01641B10.1039/D3AN01641B ↗
43. 10.1186/s12951-024-02699-810.1186/s12951-024-02699-8 ↗
44. 10.1016/j.tiv.2021.10509410.1016/j.tiv.2021.105094 ↗